The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2016 | History of gene therapies
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Jane Apperley, MD from Imperial College London, London, UK discusses developments leading to gene therapies for the management of graft-versus-host-disease (GvHD) and CAR T-cells designed specifically for Acute Myeloid Leukemia (AML) and Myeloma.
